JP2015064362A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015064362A5 JP2015064362A5 JP2014218116A JP2014218116A JP2015064362A5 JP 2015064362 A5 JP2015064362 A5 JP 2015064362A5 JP 2014218116 A JP2014218116 A JP 2014218116A JP 2014218116 A JP2014218116 A JP 2014218116A JP 2015064362 A5 JP2015064362 A5 JP 2015064362A5
- Authority
- JP
- Japan
- Prior art keywords
- acid
- level
- sample
- lpc
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 25
- 239000000090 biomarker Substances 0.000 claims 21
- 239000000523 sample Substances 0.000 claims 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 11
- 239000008103 glucose Substances 0.000 claims 11
- 208000002705 Glucose Intolerance Diseases 0.000 claims 10
- 201000009104 prediabetes syndrome Diseases 0.000 claims 10
- 206010022489 Insulin Resistance Diseases 0.000 claims 9
- WWNNZCOKKKDOPX-UHFFFAOYSA-N N-methylnicotinate Chemical compound C[N+]1=CC=CC(C([O-])=O)=C1 WWNNZCOKKKDOPX-UHFFFAOYSA-N 0.000 claims 9
- 239000012472 biological sample Substances 0.000 claims 9
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 9
- 239000008777 Glycerylphosphorylcholine Substances 0.000 claims 8
- SUHOQUVVVLNYQR-MRVPVSSYSA-N choline alfoscerate Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-N 0.000 claims 8
- 229960004956 glycerylphosphorylcholine Drugs 0.000 claims 8
- 206010012601 diabetes mellitus Diseases 0.000 claims 7
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims 6
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 claims 6
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 claims 6
- BKAJNAXTPSGJCU-UHFFFAOYSA-N 4-methyl-2-oxopentanoic acid Chemical compound CC(C)CC(=O)C(O)=O BKAJNAXTPSGJCU-UHFFFAOYSA-N 0.000 claims 6
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 6
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims 6
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 5
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 5
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 5
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 5
- 239000005642 Oleic acid Substances 0.000 claims 5
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 5
- AFENDNXGAFYKQO-VKHMYHEASA-N (S)-2-hydroxybutyric acid Chemical compound CC[C@H](O)C(O)=O AFENDNXGAFYKQO-VKHMYHEASA-N 0.000 claims 4
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims 4
- 235000021355 Stearic acid Nutrition 0.000 claims 4
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims 4
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims 4
- 229960004488 linolenic acid Drugs 0.000 claims 4
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims 4
- 125000005645 linoleyl group Chemical group 0.000 claims 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 4
- 239000008117 stearic acid Substances 0.000 claims 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 3
- FPRKGXIOSIUDSE-SYACGTDESA-N (2z,4z,6z,8z)-docosa-2,4,6,8-tetraenoic acid Chemical compound CCCCCCCCCCCCC\C=C/C=C\C=C/C=C\C(O)=O FPRKGXIOSIUDSE-SYACGTDESA-N 0.000 claims 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims 3
- MVJLYXCJBPXRCY-UHFFFAOYSA-N 2-methylbutyl propanoate Chemical compound CCC(C)COC(=O)CC MVJLYXCJBPXRCY-UHFFFAOYSA-N 0.000 claims 3
- QHKABHOOEWYVLI-UHFFFAOYSA-N 3-methyl-2-oxobutanoic acid Chemical compound CC(C)C(=O)C(O)=O QHKABHOOEWYVLI-UHFFFAOYSA-N 0.000 claims 3
- 239000001142 4-methyl-2-oxopentanoic acid Substances 0.000 claims 3
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 3
- 235000021292 Docosatetraenoic acid Nutrition 0.000 claims 3
- 239000004471 Glycine Substances 0.000 claims 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 3
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 claims 3
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 claims 3
- 229960003624 creatine Drugs 0.000 claims 3
- 239000006046 creatine Substances 0.000 claims 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 3
- 229960000310 isoleucine Drugs 0.000 claims 3
- 229940041290 mannose Drugs 0.000 claims 3
- 238000012544 monitoring process Methods 0.000 claims 3
- 229960002969 oleic acid Drugs 0.000 claims 3
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 229940055726 pantothenic acid Drugs 0.000 claims 3
- 235000019161 pantothenic acid Nutrition 0.000 claims 3
- 239000011713 pantothenic acid Substances 0.000 claims 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 3
- 235000014393 valine Nutrition 0.000 claims 3
- 239000004474 valine Substances 0.000 claims 3
- 229940075420 xanthine Drugs 0.000 claims 3
- 206010056997 Impaired fasting glucose Diseases 0.000 claims 2
- 229940122355 Insulin sensitizer Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 claims 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 claims 1
- 102000011690 Adiponectin Human genes 0.000 claims 1
- 108010076365 Adiponectin Proteins 0.000 claims 1
- YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 claims 1
- 108010075254 C-Peptide Proteins 0.000 claims 1
- 108010023302 HDL Cholesterol Proteins 0.000 claims 1
- 102000001554 Hemoglobins Human genes 0.000 claims 1
- 108010054147 Hemoglobins Proteins 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 238000008214 LDL Cholesterol Methods 0.000 claims 1
- 108010028554 LDL Cholesterol Proteins 0.000 claims 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims 1
- 108010088847 Peptide YY Proteins 0.000 claims 1
- 102100029909 Peptide YY Human genes 0.000 claims 1
- 108010076181 Proinsulin Proteins 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 235000021588 free fatty acids Nutrition 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 235000020778 linoleic acid Nutrition 0.000 claims 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims 1
- 238000013178 mathematical model Methods 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 235000021313 oleic acid Nutrition 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000002769 thiazolinyl group Chemical group 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95028607P | 2007-07-17 | 2007-07-17 | |
| US60/950,286 | 2007-07-17 | ||
| US3762808P | 2008-03-18 | 2008-03-18 | |
| US61/037,628 | 2008-03-18 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010517019A Division JP5701601B2 (ja) | 2007-07-17 | 2008-07-17 | 糖尿病前症、心血管疾患及びその他のメタボリックシンドローム関連障害のバイオマーカー並びにその使用方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015236454A Division JP2016102797A (ja) | 2007-07-17 | 2015-12-03 | 糖尿病前症、心血管疾患及びその他のメタボリックシンドローム関連障害のバイオマーカー並びにその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015064362A JP2015064362A (ja) | 2015-04-09 |
| JP2015064362A5 true JP2015064362A5 (enExample) | 2015-05-28 |
| JP5876918B2 JP5876918B2 (ja) | 2016-03-02 |
Family
ID=40282019
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010517019A Active JP5701601B2 (ja) | 2007-07-17 | 2008-07-17 | 糖尿病前症、心血管疾患及びその他のメタボリックシンドローム関連障害のバイオマーカー並びにその使用方法 |
| JP2014218116A Active JP5876918B2 (ja) | 2007-07-17 | 2014-10-27 | 糖尿病前症、心血管疾患及びその他のメタボリックシンドローム関連障害のバイオマーカー並びにその使用方法 |
| JP2015236454A Pending JP2016102797A (ja) | 2007-07-17 | 2015-12-03 | 糖尿病前症、心血管疾患及びその他のメタボリックシンドローム関連障害のバイオマーカー並びにその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010517019A Active JP5701601B2 (ja) | 2007-07-17 | 2008-07-17 | 糖尿病前症、心血管疾患及びその他のメタボリックシンドローム関連障害のバイオマーカー並びにその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015236454A Pending JP2016102797A (ja) | 2007-07-17 | 2015-12-03 | 糖尿病前症、心血管疾患及びその他のメタボリックシンドローム関連障害のバイオマーカー並びにその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US8187830B2 (enExample) |
| EP (1) | EP2164977B1 (enExample) |
| JP (3) | JP5701601B2 (enExample) |
| AU (1) | AU2008279778B2 (enExample) |
| BR (1) | BRPI0815095B1 (enExample) |
| CA (1) | CA2690541A1 (enExample) |
| ES (1) | ES2443540T3 (enExample) |
| MX (3) | MX341954B (enExample) |
| WO (1) | WO2009014639A2 (enExample) |
Families Citing this family (128)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2647122A1 (en) * | 2006-03-24 | 2007-10-04 | Metanomics Gmbh | Means and method for diagnosing diabetes |
| EP2053395A4 (en) * | 2006-08-04 | 2010-04-21 | Ajinomoto Kk | METABOLIC SYNDROME EVALUATION PROCEDURES, METABOLIC SYNDROME EVALUATION DEVICE, METABOLIC SYNDROME EVALUATION PROCEDURES, METABOLIC SYNDROME EVALUATION SYSTEM, METABOLIC SYNDROME EVALUATION PROGRAM AND RECORDING MEDIUM AND METHOD FOR SEARCHING FOR A PROPHYLACTIC / soothing SUBSTANCE FOR METABOLIC SYNDROME |
| US9867530B2 (en) | 2006-08-14 | 2018-01-16 | Volcano Corporation | Telescopic side port catheter device with imaging system and method for accessing side branch occlusions |
| EP2172775A4 (en) * | 2007-06-25 | 2010-12-01 | Ajinomoto Kk | METHOD OF EVALUATING VISCERAL GREASE ACCUMULATION |
| US9596993B2 (en) | 2007-07-12 | 2017-03-21 | Volcano Corporation | Automatic calibration systems and methods of use |
| WO2009009802A1 (en) | 2007-07-12 | 2009-01-15 | Volcano Corporation | Oct-ivus catheter for concurrent luminal imaging |
| JP5524835B2 (ja) | 2007-07-12 | 2014-06-18 | ヴォルカノ コーポレイション | 生体内撮像用カテーテル |
| EP2164977B1 (en) | 2007-07-17 | 2013-10-30 | Metabolon, Inc. | Biomarkers for pre-diabetes and methods using the same |
| EP2209001A4 (en) * | 2007-10-25 | 2010-10-27 | Ajinomoto Kk | METHOD FOR ASSESSING STROKEN GLUCOSE TOLERANCE |
| ES2402142T3 (es) * | 2007-11-02 | 2013-04-29 | Metabolon, Inc. | Biomarcadores para la enfermedad del hígado graso y métodos que utilizan los mismos |
| CN107254517A (zh) | 2008-01-18 | 2017-10-17 | 哈佛大学校长及研究员协会 | 在体液中检测疾病或病症标志的方法 |
| EP2265957B1 (en) * | 2008-04-09 | 2013-07-24 | B.R.A.H.M.S GmbH | Pro-endothelin-1 for the prediction of impaired peak oxygen consumption |
| US20100222315A1 (en) * | 2008-09-24 | 2010-09-02 | Harbor BioSciencs, Inc. | Patient populations and treatment methods |
| EP4016105A1 (en) * | 2008-10-20 | 2022-06-22 | Liposcience, Inc. | Lipoprotein insulin resistance indexes and related methods, systems and computer program for generating same |
| AU2010224175A1 (en) | 2009-03-10 | 2011-09-29 | Duke University | Predicting coronary artery disease and risk of cardiovascular events |
| US20120122981A1 (en) * | 2009-03-31 | 2012-05-17 | Yun Fu Hu | Biomarkers Related to Insulin Resistance and Methods using the Same |
| SG10201402287TA (en) | 2009-05-11 | 2014-07-30 | Berg Llc | Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
| WO2011031803A1 (en) * | 2009-09-08 | 2011-03-17 | Nodality, Inc. | Analysis of cell networks |
| JP5787339B2 (ja) * | 2009-12-28 | 2015-09-30 | 学校法人福岡大学 | 糖尿病前症の検査方法 |
| JP2013522652A (ja) * | 2010-03-23 | 2013-06-13 | パーデュー・リサーチ・ファウンデーション | 代謝物プロファイリングを用いた再発乳癌の早期検出 |
| US9468657B2 (en) | 2010-06-08 | 2016-10-18 | Asahi Group Holdings, Ltd. | Lactic acid bacterium agent for improving lipid metabolism |
| CA2806304A1 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods of detecting prenatal or pregnancy-related diseases or conditions |
| CA2806291C (en) | 2010-07-23 | 2023-08-29 | President And Fellows Of Harvard College | Methods for detecting signatures of disease or conditions in bodily fluids |
| MX2013000917A (es) | 2010-07-23 | 2013-07-05 | Harvard College | Metodos para detectar las enfermedades o condiciones usando celulas fagociticas. |
| US20130210647A1 (en) | 2010-07-23 | 2013-08-15 | President And Fellows Of Harvard College | Methods of Detecting Cardiovascular Diseases or Conditions |
| CA2806293A1 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods of detecting autoimmune or immune-related diseases or conditions |
| US20130126725A1 (en) * | 2010-07-30 | 2013-05-23 | Technische Universität Graz | Analyses of Analytes by Mass Spectrometry with Values in at Least 3 Dimensions |
| WO2012058298A1 (en) * | 2010-10-26 | 2012-05-03 | Mayo Foundation For Medical Education And Research | Biomarkers of reduced insulin action |
| US11141063B2 (en) | 2010-12-23 | 2021-10-12 | Philips Image Guided Therapy Corporation | Integrated system architectures and methods of use |
| EP2656074A4 (en) * | 2010-12-23 | 2014-10-29 | Metanomics Health Gmbh | MEDIUM AND METHOD FOR PREDICTING DIABETES |
| US11040140B2 (en) | 2010-12-31 | 2021-06-22 | Philips Image Guided Therapy Corporation | Deep vein thrombosis therapeutic methods |
| WO2012116074A1 (en) * | 2011-02-22 | 2012-08-30 | Mayo Foundation For Medical Education And Research | Biomarkers of insulin sensitivity |
| WO2012138765A1 (en) | 2011-04-04 | 2012-10-11 | Berg Pharma Llc | Methods of treating central nervous system tumors |
| JP6260275B2 (ja) | 2011-06-30 | 2018-01-17 | 味の素株式会社 | 脂肪肝の評価方法、脂肪肝評価装置、脂肪肝評価方法、脂肪肝評価プログラム、脂肪肝評価システム、および端末装置 |
| EP3527990A1 (en) * | 2011-07-28 | 2019-08-21 | metanomics GmbH | Use of sm_sphingomyelin (d18:1, c23:1) as a marker for heart failure |
| WO2013033592A1 (en) | 2011-08-31 | 2013-03-07 | Volcano Corporation | Optical-electrical rotary joint and methods of use |
| JP6158186B2 (ja) * | 2011-09-14 | 2017-07-05 | メタボロン，インコーポレイテッド | インスリン抵抗性に関連するバイオマーカーおよびそれを使用する方法 |
| WO2013122469A2 (en) * | 2012-02-17 | 2013-08-22 | Rijksuniversiteit Groningen | Prediction of the efficacy of a medicament on renal or cardiovascular clinical outcomes |
| EP2642295A1 (en) | 2012-03-22 | 2013-09-25 | Nestec S.A. | 1-O-alkyl-2-acylglycerophosphocholine (PC-O) 40:1 as biomarker for healthy ageing |
| EP2642294A1 (en) * | 2012-03-22 | 2013-09-25 | Nestec S.A. | Phenylacetylglutamine as biomarker for healthy ageing |
| EP2642293A1 (en) * | 2012-03-22 | 2013-09-25 | Nestec S.A. | 9-oxo-octadecadienoic acid (9-oxo-HODE)as as biomarker for healthy ageing |
| EP2642297A1 (en) * | 2012-03-22 | 2013-09-25 | Nestec S.A. | Hydroxy-sphingomyelin 22:1 as biomarker for healthy ageing |
| EP2642296A1 (en) * | 2012-03-22 | 2013-09-25 | Nestec S.A. | p-Cresol sulphate as biomarker for healthy ageing |
| IN2014DN10127A (enExample) * | 2012-06-05 | 2015-08-21 | Nestec Sa | |
| US9361429B2 (en) | 2012-06-08 | 2016-06-07 | Liposcience, Inc. | Multi-parameter diabetes risk evaluations |
| US9928345B2 (en) | 2012-06-08 | 2018-03-27 | Liposciences, Inc. | Multiple-marker risk parameters predictive of conversion to diabetes |
| US20140179805A1 (en) | 2012-06-15 | 2014-06-26 | Harry Stylli | Methods of detecting diseases or conditions |
| AU2013273984A1 (en) | 2012-06-15 | 2015-01-22 | Harry Stylli | Methods of detecting diseases or conditions using circulating diseased cells |
| EP2867669B1 (en) | 2012-06-27 | 2016-12-21 | Metanomics Health GmbH | Methods for identifying diabetes drugs |
| CN104769434B (zh) * | 2012-08-13 | 2018-01-02 | 亥姆霍兹慕尼黑中心德国研究健康与环境有限责任公司 | 用于2型糖尿病的生物标志物 |
| US20140324460A1 (en) * | 2012-09-26 | 2014-10-30 | Health Diagnostic Laboratory, Inc. | Method for determining and managing total cardiodiabetes risk |
| US9367965B2 (en) | 2012-10-05 | 2016-06-14 | Volcano Corporation | Systems and methods for generating images of tissue |
| US20140100454A1 (en) | 2012-10-05 | 2014-04-10 | Volcano Corporation | Methods and systems for establishing parameters for three-dimensional imaging |
| US11272845B2 (en) | 2012-10-05 | 2022-03-15 | Philips Image Guided Therapy Corporation | System and method for instant and automatic border detection |
| US9292918B2 (en) | 2012-10-05 | 2016-03-22 | Volcano Corporation | Methods and systems for transforming luminal images |
| CA2887421A1 (en) | 2012-10-05 | 2014-04-10 | David Welford | Systems and methods for amplifying light |
| US10070827B2 (en) | 2012-10-05 | 2018-09-11 | Volcano Corporation | Automatic image playback |
| US9286673B2 (en) | 2012-10-05 | 2016-03-15 | Volcano Corporation | Systems for correcting distortions in a medical image and methods of use thereof |
| US10568586B2 (en) | 2012-10-05 | 2020-02-25 | Volcano Corporation | Systems for indicating parameters in an imaging data set and methods of use |
| US9324141B2 (en) | 2012-10-05 | 2016-04-26 | Volcano Corporation | Removal of A-scan streaking artifact |
| US9858668B2 (en) | 2012-10-05 | 2018-01-02 | Volcano Corporation | Guidewire artifact removal in images |
| US9307926B2 (en) | 2012-10-05 | 2016-04-12 | Volcano Corporation | Automatic stent detection |
| US9840734B2 (en) | 2012-10-22 | 2017-12-12 | Raindance Technologies, Inc. | Methods for analyzing DNA |
| JP6322210B2 (ja) | 2012-12-13 | 2018-05-09 | ボルケーノ コーポレイション | 標的化された挿管のためのデバイス、システム、および方法 |
| US10942022B2 (en) | 2012-12-20 | 2021-03-09 | Philips Image Guided Therapy Corporation | Manual calibration of imaging system |
| US11406498B2 (en) | 2012-12-20 | 2022-08-09 | Philips Image Guided Therapy Corporation | Implant delivery system and implants |
| CA2895770A1 (en) | 2012-12-20 | 2014-07-24 | Jeremy Stigall | Locating intravascular images |
| US9709379B2 (en) | 2012-12-20 | 2017-07-18 | Volcano Corporation | Optical coherence tomography system that is reconfigurable between different imaging modes |
| US10939826B2 (en) | 2012-12-20 | 2021-03-09 | Philips Image Guided Therapy Corporation | Aspirating and removing biological material |
| CA2895502A1 (en) | 2012-12-20 | 2014-06-26 | Jeremy Stigall | Smooth transition catheters |
| CA2895993A1 (en) | 2012-12-21 | 2014-06-26 | Jason Spencer | System and method for graphical processing of medical data |
| CA2895940A1 (en) | 2012-12-21 | 2014-06-26 | Andrew Hancock | System and method for multipath processing of image signals |
| US9612105B2 (en) | 2012-12-21 | 2017-04-04 | Volcano Corporation | Polarization sensitive optical coherence tomography system |
| CA2896004A1 (en) | 2012-12-21 | 2014-06-26 | Nathaniel J. Kemp | Power-efficient optical buffering using optical switch |
| US10993694B2 (en) | 2012-12-21 | 2021-05-04 | Philips Image Guided Therapy Corporation | Rotational ultrasound imaging catheter with extended catheter body telescope |
| US9383263B2 (en) | 2012-12-21 | 2016-07-05 | Volcano Corporation | Systems and methods for narrowing a wavelength emission of light |
| US10058284B2 (en) | 2012-12-21 | 2018-08-28 | Volcano Corporation | Simultaneous imaging, monitoring, and therapy |
| US9486143B2 (en) | 2012-12-21 | 2016-11-08 | Volcano Corporation | Intravascular forward imaging device |
| JP2016501625A (ja) | 2012-12-21 | 2016-01-21 | ジェローム マイ， | 可変線密度での超音波撮像 |
| WO2014100530A1 (en) | 2012-12-21 | 2014-06-26 | Whiseant Chester | System and method for catheter steering and operation |
| US9910047B2 (en) | 2013-01-31 | 2018-03-06 | Metabolon, Inc. | Biomarkers related to insulin resistance progression and methods using the same |
| AU2014210871A1 (en) * | 2013-01-31 | 2015-08-13 | Adaerata, Limited Partnership | Type 2 diabetes biomarkers and uses thereof |
| BR112015019453A2 (pt) * | 2013-02-14 | 2017-07-18 | Metanomics Health Gmbh | método, dispositivo e conjunto para a avaliação da qualidade de uma amostra biológica e uso de pelo menos um biorrotulador |
| US10226597B2 (en) | 2013-03-07 | 2019-03-12 | Volcano Corporation | Guidewire with centering mechanism |
| CN105103163A (zh) | 2013-03-07 | 2015-11-25 | 火山公司 | 血管内图像中的多模态分割 |
| WO2014164366A1 (en) | 2013-03-09 | 2014-10-09 | Harry Stylli | Methods of detecting cancer |
| US11585814B2 (en) | 2013-03-09 | 2023-02-21 | Immunis.Ai, Inc. | Methods of detecting prostate cancer |
| US20140276923A1 (en) | 2013-03-12 | 2014-09-18 | Volcano Corporation | Vibrating catheter and methods of use |
| JP2016521138A (ja) | 2013-03-12 | 2016-07-21 | コリンズ，ドナ | 冠動脈微小血管疾患を診断するためのシステム及び方法 |
| US20140278121A1 (en) * | 2013-03-13 | 2014-09-18 | Robust for Life, Inc. | Systems and methods for network-based calculation and reporting of metabolic risk |
| US9301687B2 (en) | 2013-03-13 | 2016-04-05 | Volcano Corporation | System and method for OCT depth calibration |
| CN105120759B (zh) | 2013-03-13 | 2018-02-23 | 火山公司 | 用于从旋转血管内超声设备产生图像的系统和方法 |
| US11026591B2 (en) | 2013-03-13 | 2021-06-08 | Philips Image Guided Therapy Corporation | Intravascular pressure sensor calibration |
| US10426590B2 (en) | 2013-03-14 | 2019-10-01 | Volcano Corporation | Filters with echogenic characteristics |
| US10219887B2 (en) | 2013-03-14 | 2019-03-05 | Volcano Corporation | Filters with echogenic characteristics |
| US12343198B2 (en) | 2013-03-14 | 2025-07-01 | Philips Image Guided Therapy Corporation | Delivery catheter having imaging capabilities |
| US10292677B2 (en) | 2013-03-14 | 2019-05-21 | Volcano Corporation | Endoluminal filter having enhanced echogenic properties |
| MX380565B (es) | 2013-04-08 | 2025-03-12 | Berg Llc | Terapias combinadas de coenzima q10 para el tratamiento de cáncer. |
| CA2921530A1 (en) | 2013-07-18 | 2015-01-22 | True Health Diagnostics, Llc | Method of determination of risk of 2 hour blood glucose equal to or greater than 140 mg/dl |
| AU2014315186B2 (en) | 2013-09-04 | 2020-02-27 | Berg Llc | Methods of treatment of cancer by continuous infusion of coenzyme Q10 |
| GB2524230A (en) * | 2014-02-14 | 2015-09-23 | Asda Stores Ltd | Transaction processing system and transaction processing method |
| WO2016040843A1 (en) | 2014-09-11 | 2016-03-17 | Harry Stylli | Methods of detecting prostate cancer |
| WO2016103390A1 (ja) * | 2014-12-25 | 2016-06-30 | 株式会社日立製作所 | インスリン分泌能分析装置、当該装置を備えるインスリン分泌能分析システム及びインスリン分泌能分析方法 |
| HUE056203T2 (hu) * | 2015-01-09 | 2022-01-28 | Global Genomics Group Llc | Vér alapú biomarkerek atheroszklerotikus koszorúsér betegség diagnosztizálására |
| US10451641B2 (en) | 2015-03-13 | 2019-10-22 | Duke University | Compositions and methods for metabolic profiling in subjects with heart failure with preserved ejection fraction |
| JP6051258B2 (ja) * | 2015-04-15 | 2016-12-27 | ライオン株式会社 | 脂質異常症への罹患しやすさを試験する方法 |
| KR101795689B1 (ko) * | 2015-04-30 | 2017-11-30 | 경희대학교 산학협력단 | 혈관 협착 질환 진단용 마커 및 이의 용도 |
| US20170189350A1 (en) | 2015-11-16 | 2017-07-06 | Berg Llc | Methods of treatment of temozolomide-resistant glioma using coenzyme q10 |
| WO2018094204A1 (en) * | 2016-11-17 | 2018-05-24 | Arivale, Inc. | Determining relationships between risks for biological conditions and dynamic analytes |
| US11881311B1 (en) | 2017-02-17 | 2024-01-23 | BioAge Labs, Inc. | Survival prediction using metabolomic profiles |
| JP2018141728A (ja) * | 2017-02-28 | 2018-09-13 | トヨタ自動車株式会社 | 生活習慣病の診断方法 |
| EP3713478A4 (en) | 2017-11-22 | 2021-11-03 | Mayo Foundation for Medical Education and Research | METHODS AND MATERIALS FOR EVALUATION AND TREATMENT OF OBESITAS |
| US20200041496A1 (en) * | 2018-08-01 | 2020-02-06 | Joshua Health Care LLC | Methods for Identifying and Treating Mammalian Subjects with Insulin Resistance |
| JP7189537B2 (ja) * | 2019-06-27 | 2022-12-14 | サンスター株式会社 | 血液試料の酸化ｈｄｌ量の反映値を測定する工程を含む、測定方法 |
| CN114096838B (zh) * | 2019-07-08 | 2025-07-11 | 株式会社岛津制作所 | 移植用脏器的功能评价方法、移植用脏器的功能评价程序以及移植用脏器的功能评价装置 |
| US20240085432A1 (en) * | 2019-10-11 | 2024-03-14 | The Regents Of The University Of California | Metabolic profile screening for gestational diabetes |
| CN115552025A (zh) * | 2020-02-05 | 2022-12-30 | 克利夫兰诊所基金会 | 基于苯乙酰谷氨酰胺水平的疾病检测和治疗 |
| CN113866284B (zh) * | 2020-06-30 | 2023-09-05 | 上海脉示生物技术有限公司 | 一组用于心力衰竭诊断的肠道微生物代谢标志物及其应用 |
| CN112684064B (zh) * | 2020-12-08 | 2022-05-17 | 安徽农业大学 | 用于筛选抗应激胁迫肉羊的血清代谢标志物及其应用 |
| WO2022133034A1 (en) * | 2020-12-16 | 2022-06-23 | St. Jude Children's Research Hospital, Inc. | Methods of treating disorders associated with castor |
| CN113325117B (zh) * | 2021-06-25 | 2022-07-15 | 中国医学科学院北京协和医院 | 一组生物标记物在制备预测静脉内平滑肌瘤病进展的试剂盒中的应用 |
| CN115023608B (zh) * | 2021-11-30 | 2024-01-19 | 江苏品生医疗科技集团有限公司 | 预测受试者患有糖尿病的可能性的标记物及其应用 |
| EP4468945A1 (en) * | 2022-01-28 | 2024-12-04 | GATC Health Corp | Biomarkers for early detection of diabetes |
| CN114965733B (zh) * | 2022-04-07 | 2023-12-01 | 中国人民解放军总医院第一医学中心 | 结直肠进展期腺瘤诊断代谢标志物组合及其应用 |
| WO2025019706A1 (en) * | 2023-07-19 | 2025-01-23 | Ahara Corporation | Systems and methods for generating a nutrition program |
| CN117347529A (zh) * | 2023-11-22 | 2024-01-05 | 中国人民解放军军事科学院军事医学研究院 | 肠道菌群和代谢物的应用以及高原心脏病的预测系统 |
| JP2025112741A (ja) * | 2024-01-22 | 2025-08-01 | 富士フイルム株式会社 | 情報管理装置及び情報管理装置の作動方法並びに情報管理プログラム |
| CN119846232B (zh) * | 2025-01-21 | 2025-10-03 | 宁夏农林科学院动物科学研究所(宁夏草畜工程技术研究中心) | 一种早期诊断奶牛隐性乳房炎的生物标志物组合及其应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5367052A (en) * | 1987-04-27 | 1994-11-22 | Amylin Pharmaceuticals, Inc. | Amylin peptides |
| KR19990007908A (ko) * | 1996-02-20 | 1999-01-25 | 히라다다다시 | 1,5-안히드로글루시톨의 정량법 |
| JP2938048B1 (ja) * | 1998-06-30 | 1999-08-23 | 技術研究組合医療福祉機器研究所 | 代謝機能測定装置 |
| US6140067A (en) * | 1999-04-30 | 2000-10-31 | Mitokor | Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus |
| JP3975279B2 (ja) * | 1999-11-01 | 2007-09-12 | 旭化成ファーマ株式会社 | 糖尿病予備群の検査方法 |
| CA2443806A1 (en) * | 2000-04-14 | 2002-10-25 | Metabolon, Inc. | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| US7329489B2 (en) * | 2000-04-14 | 2008-02-12 | Matabolon, Inc. | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| RU2003104808A (ru) * | 2000-08-07 | 2004-08-20 | Ранбакси Сигниче Ллк (Us) | Жидкий состав метформина |
| CN1533435A (zh) * | 2001-06-01 | 2004-09-29 | 克林杰尼克斯公司 | 用于诊断及治疗胰岛素抗性及相关病症之方法和试剂 |
| US7425545B2 (en) * | 2001-07-25 | 2008-09-16 | Isis Pharmaceuticals, Inc. | Modulation of C-reactive protein expression |
| JP4100673B2 (ja) * | 2001-12-07 | 2008-06-11 | 日本化薬株式会社 | 肝糖放出の検査方法 |
| JP2003204800A (ja) * | 2002-01-15 | 2003-07-22 | Sumitomo Pharmaceut Co Ltd | 糖代謝異常疾患マーカーおよびその利用 |
| WO2003087768A2 (en) * | 2002-04-12 | 2003-10-23 | Mitokor | Targets for therapeutic intervention identified in the mitochondrial proteome |
| US20060148690A1 (en) * | 2002-07-08 | 2006-07-06 | Lydie Bougueleret | Secreted peptides |
| JP2005006645A (ja) * | 2003-05-22 | 2005-01-13 | Sumitomo Chemical Co Ltd | インスリン応答性の評価方法 |
| US7648825B2 (en) * | 2003-06-20 | 2010-01-19 | University Of Florida Research Foundation, Inc. | Biomarkers for differentiating between type 1 and type 2 diabetes |
| US7345142B2 (en) * | 2004-01-27 | 2008-03-18 | Compugen Ltd. | Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of cardiac disease |
| JP4547173B2 (ja) * | 2004-03-17 | 2010-09-22 | シスメックス株式会社 | 糖尿病診療支援システム |
| JP4533042B2 (ja) * | 2004-08-25 | 2010-08-25 | 裕 笹川 | 糖尿病および糖代謝異常を判断する方法 |
| US20080261317A1 (en) * | 2004-09-07 | 2008-10-23 | Fifer Michael A | Methods of Detecting Myocardial Ischemia and Myocardial Infarction |
| JP4522222B2 (ja) * | 2004-10-22 | 2010-08-11 | 扶桑薬品工業株式会社 | 血中脂肪酸濃度測定による心疾患の早期診断方法 |
| JP2008523398A (ja) * | 2004-12-14 | 2008-07-03 | エフ．ホフマン−ラ ロシュ アーゲー | インスリン抵抗性の標的／マーカーとしてのｃｄ９９ |
| WO2006066263A1 (en) | 2004-12-17 | 2006-06-22 | Entelos, Inc. | Assessing insulin resistance using biomarkers |
| WO2006073195A1 (ja) * | 2005-01-07 | 2006-07-13 | Biomarker Science Co., Ltd | 糖尿病の予知・診断方法および糖尿病予知・診断用キット |
| FR2890079B1 (fr) * | 2005-08-26 | 2007-11-30 | Alain Rambach | Detection des salmonelles lactose + |
| WO2007038670A2 (en) * | 2005-09-30 | 2007-04-05 | Perlegen Sciences, Inc. | Methods and compositions for screening and treatment of disorders of blood glucose regulation |
| AU2006302031A1 (en) * | 2005-10-11 | 2007-04-19 | Tethys Bioscience, Inc. | Diabetes-associated markers and methods of use thereof |
| JP2007127423A (ja) * | 2005-10-31 | 2007-05-24 | Toray Ind Inc | ３−ヒドロキシ酪酸の測定方法およびキット |
| CA2647122A1 (en) * | 2006-03-24 | 2007-10-04 | Metanomics Gmbh | Means and method for diagnosing diabetes |
| EP2293077B1 (en) * | 2007-03-26 | 2014-05-14 | BG Medicine, Inc. | Methods for detecting coronary artery disease |
| EP2164977B1 (en) * | 2007-07-17 | 2013-10-30 | Metabolon, Inc. | Biomarkers for pre-diabetes and methods using the same |
| US20120122981A1 (en) * | 2009-03-31 | 2012-05-17 | Yun Fu Hu | Biomarkers Related to Insulin Resistance and Methods using the Same |
| EP2656074A4 (en) * | 2010-12-23 | 2014-10-29 | Metanomics Health Gmbh | MEDIUM AND METHOD FOR PREDICTING DIABETES |
-
2008
- 2008-07-17 EP EP08780229.4A patent/EP2164977B1/en active Active
- 2008-07-17 BR BRPI0815095-8A patent/BRPI0815095B1/pt active IP Right Grant
- 2008-07-17 AU AU2008279778A patent/AU2008279778B2/en active Active
- 2008-07-17 MX MX2013008169A patent/MX341954B/es unknown
- 2008-07-17 WO PCT/US2008/008756 patent/WO2009014639A2/en not_active Ceased
- 2008-07-17 ES ES08780229.4T patent/ES2443540T3/es active Active
- 2008-07-17 MX MX2016009020A patent/MX377928B/es unknown
- 2008-07-17 CA CA2690541A patent/CA2690541A1/en not_active Abandoned
- 2008-07-17 MX MX2010000414A patent/MX2010000414A/es active IP Right Grant
- 2008-07-17 US US12/218,980 patent/US8187830B2/en active Active
- 2008-07-17 JP JP2010517019A patent/JP5701601B2/ja active Active
-
2012
- 2012-04-27 US US13/457,620 patent/US8546098B2/en active Active
-
2013
- 2013-08-14 US US13/966,475 patent/US8809008B2/en active Active
-
2014
- 2014-07-07 US US14/324,689 patent/US9250225B2/en active Active
- 2014-10-27 JP JP2014218116A patent/JP5876918B2/ja active Active
-
2015
- 2015-12-03 JP JP2015236454A patent/JP2016102797A/ja active Pending
- 2015-12-21 US US14/975,988 patent/US10175233B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015064362A5 (enExample) | ||
| JP2012522989A5 (enExample) | ||
| JP2010537157A5 (enExample) | ||
| Montesano et al. | Validation of a method for the targeted analysis of 96 drugs in hair by UPLC–MS/MS | |
| WO2011133668A3 (en) | Methods and compositions for the treatment of cancer | |
| HK1199754A1 (en) | Method for monitoring, diagnosis and/or prognosis of acute kidney injury in early stage | |
| EP3865135A3 (en) | Neuroactive steroids for use in therapy | |
| EP4335931A3 (en) | Therapeutic and diagnostic methods for cancer | |
| WO2015094995A3 (en) | Gene signature biomarkers of tumor response to pd-1 antagonists | |
| EA201391017A1 (ru) | Способы и готовые лекарственные формы для лечения болезни альцгеймера | |
| JP2016500110A5 (enExample) | ||
| WO2009090553A3 (en) | Compositions and methods of detecting post-stop peptides | |
| JP7123329B2 (ja) | 腎臓病の予後予測方法及びシステム | |
| WO2015164620A1 (en) | System and method for monitoring the health of dialysis patients | |
| JP2016520192A5 (enExample) | ||
| WO2015094996A3 (en) | Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists | |
| MX2017003370A (es) | Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica. | |
| JP2014532168A5 (enExample) | ||
| JP2015511721A5 (enExample) | ||
| WO2012032345A3 (en) | Biomarker signatures and uses thereof | |
| WO2015049390A3 (en) | Kidney disease biomarker | |
| EP3178846A3 (en) | Novel phosphorylation of cardiac troponin i as a monitor for cardiac injury | |
| JP2014505254A5 (enExample) | ||
| WO2018026969A3 (en) | Plazomicin antibodies and methods of use | |
| WO2013186513A3 (en) | Apparatus |